Clinilabs Drug Development Corp. announced enrollment has begun in a phase 1/2a clinical trial for the use of CYB003, a novel psilocybin analog that will be evaluated for the treatment of major depressive disorder.
CYB003 is being developed by Cybin Inc., a biopharmaceutical company, which announced it received investigational new drug clearance from the FDA at the end of June. The drug is the first novel psilocybin analog to enter clinical development, according to a press release from Clinilabs.
“Clinilabs is honored to be working with Cybin, an innovator in the development of novel